Cumberland Pharmaceuticals Inc. (CPIX) Posts Earnings Results
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) posted its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, Morningstar.com reports. Cumberland Pharmaceuticals had a positive return on equity of 1.93% and a negative net margin of 5.63%.
Cumberland Pharmaceuticals (NASDAQ:CPIX) opened at 6.84 on Wednesday. The company’s market cap is $109.67 million. The stock’s 50 day moving average price is $6.94 and its 200-day moving average price is $6.46. Cumberland Pharmaceuticals has a 52-week low of $4.40 and a 52-week high of $7.49.
TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/08/cumberland-pharmaceuticals-inc-cpix-releases-earnings-results.html.
Several large investors have recently modified their holdings of the stock. Essex Investment Management Co. LLC boosted its stake in shares of Cumberland Pharmaceuticals by 45.8% in the second quarter. Essex Investment Management Co. LLC now owns 15,959 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 5,014 shares during the last quarter. Ameriprise Financial Inc. bought a new position in Cumberland Pharmaceuticals during the first quarter valued at approximately $165,000. Acadian Asset Management LLC boosted its position in Cumberland Pharmaceuticals by 3.4% in the first quarter. Acadian Asset Management LLC now owns 130,430 shares of the specialty pharmaceutical company’s stock valued at $905,000 after buying an additional 4,257 shares during the last quarter. Renaissance Technologies LLC boosted its position in Cumberland Pharmaceuticals by 4.0% in the fourth quarter. Renaissance Technologies LLC now owns 257,000 shares of the specialty pharmaceutical company’s stock valued at $1,414,000 after buying an additional 9,900 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Cumberland Pharmaceuticals by 0.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 852,976 shares of the specialty pharmaceutical company’s stock valued at $4,691,000 after buying an additional 2,791 shares during the last quarter. 34.50% of the stock is owned by institutional investors and hedge funds.
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.
Receive News & Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.